<DOC>
	<DOC>NCT02238535</DOC>
	<brief_summary>To assess the effectiveness of the synthetic analogue of prostacyclin in postembolic residual pulmonary hypertension.</brief_summary>
	<brief_title>Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Patients with pulmonary embolism after undergone surgical treatment (intravascular thrombolysis, catheter thrombus fragmentation) Patients with preserved thromboembolism in the pulmonary circulation system and mean pressure in the pulmonary artery of more than 25 mm Hg Patient did not sign the informed consent. Mean pulmonary artery pressure after surgical treatment less than 25 mm Hg Age above 75 years. Patients with an increased risk of bleeding including gastric ulcer and 12 duodenal ulcer in acute, hemorrhagic stroke. Severe coronary artery disease (unstable angina, myocardial infarction within the last 6 months). Acute heart failure or CHF IV in NYHA. Severe arrhythmias. Pregnancy, lactation. The presence of severe diseases of other organ systems that may result in death during the first year after surgery.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>